Welcome to our dedicated page for IRADIMED SEC filings (Ticker: IRMD), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
iRadimed Corporation filings document the public-company reporting for a Nasdaq-listed medical-device manufacturer focused on MRI-compatible infusion and patient-monitoring systems. Form 8-K reports furnish quarterly and annual operating results, dividend announcements, guidance updates and other material events tied to the company’s common stock.
Proxy and governance filings describe annual meeting proposals, director elections, auditor ratification, executive compensation, board committee matters and shareholder voting results. Other 8-K disclosures record board composition changes and related committee assignments, providing formal records of governance and capital-structure matters for IRMD.
IRADIMED CORP director and CEO Roger E. Susi reported open-market sales of 7,500 shares of Common Stock, executed indirectly through the Phillip Susi 2008 Dynasty Trust. The sales occurred on March 23–24, 2026 at prices around $100 per share, including transactions at $99.58, $100.03, $100.71, $100.70 and $102.02 per share.
A footnote states these trades were carried out under a pre-arranged Rule 10b5-1 trading plan adopted on November 5, 2025, indicating a scheduled selling program rather than ad hoc market timing. After the transactions, the Phillip Susi 2008 Dynasty Trust held 2,232,500 shares, while other indirect holdings included 2,062,500 shares in the Matthew Susi 2008 Dynasty Trust and 162,950 shares in the Roger E. Susi Revocable Trust as of March 23, 2026. Susi disclaims beneficial ownership of these securities except to the extent of his pecuniary interest.
IRADIMED CORP director and CEO Roger E. Susi reported indirect open-market sales of company common stock through the Phillip Susi 2008 Dynasty Trust. On March 16–17, 2026, the trust sold a total of 7,500 shares at weighted average prices of about $101.18, $101.68 and $102.43 per share.
The sales were made under a pre-arranged Rule 10b5-1 trading plan adopted on November 5, 2025, indicating they were scheduled in advance. After these transactions, the Phillip Susi 2008 Dynasty Trust holds 2,240,000 shares. The filing also lists additional indirect holdings of 162,950 shares via the Roger E. Susi Revocable Trust and 2,062,500 shares via the Matthew Susi 2008 Dynasty Trust, with Susi disclaiming beneficial ownership beyond his pecuniary interest.
IRADIMED CORP’s CEO, president and chairman Roger E. Susi reported indirect open‑market sales of company common stock by the Phillip Susi 2008 Dynasty Trust. The trust sold 5,000 shares on March 9, 2026 at a weighted average price of $100.04 per share and 2,500 shares on March 10, 2026 at a weighted average price of $100.11 per share. These sales were executed under a pre‑arranged Rule 10b5‑1 trading plan adopted on November 5, 2025. Following the March 10 sale, the dynasty trust held 2,247,500 shares indirectly, and additional indirect holdings are reported for the Roger E. Susi Revocable Trust and the Matthew Susi 2008 Dynasty Trust. The reporting person disclaims beneficial ownership of the reported securities except to the extent of his pecuniary interest.
IRADIMED CORP director and CEO Roger E. Susi reported planned insider sales of company stock through a family trust. A total of 7,500 shares of common stock were sold on March 6, 2026 by the Phillip Susi 2008 Dynasty Trust in open-market transactions at weighted average prices of $98.25 and $99.12 per share, under a Rule 10b5-1 trading plan adopted on November 5, 2025. Following these sales, indirect holdings reported for related trusts included 162,950 shares held by the Roger E. Susi Revocable Trust and 2,062,500 shares held by the Matthew Susi 2008 Dynasty Trust.
Iradimed Corporation (IRMD): Phillip Susi 2008 Dynasty Trust reported an intent to sell 2,362,500 shares of common stock, with the trust named as the selling holder. The excerpt also lists eight recent dispositions of 5,000 shares each on 12/08/2025, 12/15/2025, 12/22/2025, 12/29/2025, 01/05/2026, 01/12/2026, 01/20/2026, and 01/26/2026, showing proceeds for each sale.
IRadimed Corporation files its annual report describing a focused business developing MRI-compatible IV infusion pumps, patient vital-sign monitors and ferromagnetic detection devices used in hospital MRI environments.
For fiscal 2025, revenue was $83.8 million and income from operations was $26.1 million, an operating margin of about 31.2%. The company sells primarily through a U.S. direct sales force and international distributors, with the United States contributing 84% of revenue and devices accounting for 72% of revenue. Management highlights its new MRidium 3870 IV pump, 3880 monitor, and FMD1 detector, notes reliance on key suppliers, extensive FDA and international regulation, and outlines detailed risk factors, including product concentration, cybersecurity, competition, and supply-chain disruption.
IRADIMED CORP Chief Commercial Officer Jeff Chiprin reported an equity award of 1,150 restricted stock units (RSUs). These RSUs were granted under Iradimed Corporation's 2023 Equity Incentive Plan and carry no cash exercise price.
The RSUs convert into common stock on a one-for-one basis. They vest in three equal annual installments beginning on December 7, 2026, and upon each vesting date Mr. Chiprin will receive the corresponding number of common shares.
Iradimed Corp's chief financial officer John Glenn received a grant of 8,907 restricted stock units (RSUs). The RSUs were awarded under Iradimed Corporation's 2023 Equity Incentive Plan and convert into common stock on a one-for-one basis.
The award vests in three equal annual installments beginning on December 7, 2026. After vesting, Glenn will receive one share of common stock for each vested RSU, and he currently holds 8,907 RSUs directly following this grant.
IRADIMED CORP director Monty K. Allen reported an open-market sale of company stock. On 02/13/2026, he sold 1,000 shares of common stock in multiple trades at a weighted average price of $100.2563 per share. After this transaction, he directly owned 21,000 shares of IRADIMED CORP common stock.
A shareholder of Iradimed has filed a notice to sell 1,000 shares of common stock under Rule 144 through Raymond James on or around 02/13/2026, to be traded on NASDAQ. The filing lists an aggregate market value of 100,256.26 for the planned sale.
The 1,000 shares come from restricted stock units that vested on 12/07/2025 (95 shares) and 12/11/2025 (905 shares) as compensation for board service. The issuer had 12,722,377 shares outstanding when this notice was prepared.